Gardner, E.R.

imatinib cancer patient abcb 1 cyp 3a pharmacokinetic midazolam variant resistance transporter polymorphism abcg 2 protein plasma expression concentration genotype study allele difference effect chapter clearance sample 2004. inhibitor substrate treatment 2003. pharmacol analysis p-glycoprotein liver figg wd multidrug activity volunteer 2002. imatinib mesylate population pharmacogenetic tariquidar anticancer intron breast clin pharmacol exposure function transport cyp 3a genotype result disposition level brain wild-type frequency table change variability recipient mesylate cancer patients cyp 3a activity administration 2001. group cancer institute multidrug resistance blood 30 seconds determination anticancer drugs minute enzyme sparreboom mdr 1 gene j pharmacol exp number cytochrome factor